imatinibia

Imatinib, marketed as Gleevec or Glivec, is a targeted cancer therapy drug. It belongs to a class of medications called tyrosine kinase inhibitors. Imatinib specifically targets certain proteins that are involved in cancer cell growth and proliferation. It works by blocking the activity of these aberrant proteins, thereby preventing cancer cells from growing and dividing.

The primary indication for imatinib is the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). It has revolutionized the management of these conditions, transforming them from often fatal diseases into chronic, manageable ones for many patients. Imatinib is also used to treat gastrointestinal stromal tumors (GIST) that have a specific genetic mutation, as well as other rare cancers.

The development of imatinib represented a significant advancement in cancer treatment, marking a shift towards precision medicine. By targeting specific molecular pathways driving cancer, it offers a more targeted approach compared to traditional chemotherapy, which affects all rapidly dividing cells, including healthy ones. This targeted action often leads to a different side effect profile and improved efficacy for patients with specific genetic markers. While generally well-tolerated, common side effects can include fluid retention, muscle cramps, fatigue, nausea, and diarrhea. It is crucial that imatinib is prescribed and monitored by a qualified healthcare professional.